Introduction: Nucleic acid amplification tests to detect Mycobacterium tuberculosis in clinical specimens are used increasingly as a laboratory tool. We aimed to investigate the routine using pattern and the effects on therapeutic decision of diagnostic tests for tuberculosis in our hospital. Methods: In this descriptive study, we investigated retrospectively the routine using pattern and the effects on therapeutic decision of diagnostic tests for tuberculosis. Patients with discordant results were clinically evaluated retrospectively by a chest physician. Samples were tested for the presence of M. tuberculosis by a smear technique, M. tuberculosis culture growth technique (Löwen-stein-Jensen and/or BACTEC-960), and IS6110 polymerase chain reaction (PCR). Results: Culture positivity was 7.2% (83 of 1159 patients). In total, 198 (62.4%) were tested with PCR, acid-fast bacilli, and culture. On the basis of culture results as a gold standard, sensitivity, specificity, positive predictive value, and negative predictive value of PCR were 46%, 89%, 23%, and 93.5%, respectively. Conclusions: Selection of appropriate patients for further testing and exclusion of low-risk patients from microbiologic testing by experienced clinicians may help to optimize the positive predictive value of PCR. T uberculosis (TB) continues to be a major health problem worldwide. Early diagnosis of the disease and prompt initiation of treatment are important in improving patient outcome, in the prevention of multidrug-resistant mycobacteria, and in interrupting further transmission of tubercle bacilli. 1,2 Occasionally, in clinical practice, TB is diagnosed only based on clinical criteria, radiographic findings, and case-contact information. Obtaining bacteriologic confirmation is difficult in several forms of the disease because of low mycobacterial loads. Furthermore, conventional methods for diagnosis of TB are sensitive, and culture is the most reliable method in a clinical setting, but it requires 2 to 3 weeks of incubation before isolation and identification of the organism. 2-4 Therefore, it is common practice to commence early expectant treatment for TB based on provisional diagnosis before bacteriologic confirmation. This is a clinical decision based primarily on detecting symptoms that are consistent with a sub acute or chronic respiratory infection, recognizing typical features of active TB on plain chest radiographs, and identifying acid-fast bacilli (AFB) in expectorated sputum. This expectant approach to the early diagnosis of TB, although widely practiced, is not very accurate. In up to 30% of patients hospitalized with active TB, the diagnosis may be missed and thus appropriate treatment delayed. 5 On the other hand, the low specificity of chest x-rays, used for the diagnosis of smear-negative TB, risks high levels of overdiagnosis. 6 Nucleic acid amplification tests (NATs) to detect M. tuberculosis in clinical specimens are used increasingly as a laboratory tool for the diagnosis of TB because of their speed, sensitivity, and specificity. However, NATs may be unreliable because of false-positive results caused by contamination or false-negative results caused by lack of sensitivity. 4, 7, 8 Furthermore, standardized protocols are needed before these assays are introduced into routine diagnostic use. 9 Finally, it is recommended that NATs should always be performed in conjunction with microscopy and culture and that the results should be interpreted alongside the patient's clinical data. 8 The performances of several diagnostic tests for TB are well known. However, we considered that there was a need to inspect the daily clinical use of these tests. For this reason, in this descriptive study, we investigated retrospectively the routine using pattern and the effects on therapeutic decision of diagnostic tests for TB in our hospital.
T uberculosis (TB) continues to be a major health problem worldwide. Early diagnosis of the disease and prompt initiation of treatment are important in improving patient outcome, in the prevention of multidrug-resistant mycobacteria, and in interrupting further transmission of tubercle bacilli. 1, 2 Occasionally, in clinical practice, TB is diagnosed only based on clinical criteria, radiographic findings, and case-contact information. Obtaining bacteriologic confirmation is difficult in several forms of the disease because of low mycobacterial loads. Furthermore, conventional methods for diagnosis of TB are sensitive, and culture is the most reliable method in a clinical setting, but it requires 2 to 3 weeks of incubation before isolation and identification of the organism. [2] [3] [4] Therefore, it is common practice to commence early expectant treatment for TB based on provisional diagnosis before bacteriologic confirmation. This is a clinical decision based primarily on detecting symptoms that are consistent with a sub acute or chronic respiratory infection, recognizing typical features of active TB on plain chest radiographs, and identifying acid-fast bacilli (AFB) in expectorated sputum. This expectant approach to the early diagnosis of TB, although widely practiced, is not very accurate. In up to 30% of patients hospitalized with active TB, the diagnosis may be missed and thus appropriate treatment delayed. 5 On the other hand, the low specificity of chest x-rays, used for the diagnosis of smear-negative TB, risks high levels of overdiagnosis. 6 Nucleic acid amplification tests (NATs) to detect M. tuberculosis in clinical specimens are used increasingly as a laboratory tool for the diagnosis of TB because of their speed, sensitivity, and specificity. However, NATs may be unreliable because of false-positive results caused by contamination or false-negative results caused by lack of sensitivity. 4, 7, 8 Furthermore, standardized protocols are needed before these assays are introduced into routine diagnostic use. 9 Finally, it is recommended that NATs should always be performed in conjunction with microscopy and culture and that the results should be interpreted alongside the patient's clinical data. 8 The performances of several diagnostic tests for TB are well known. However, we considered that there was a need to inspect the daily clinical use of these tests. For this reason, in this descriptive study, we investigated retrospectively the routine using pattern and the effects on therapeutic decision of diagnostic tests for TB in our hospital.
METHODS

Study Design
From January 1 to December 31, 2007, clinical specimens that were sent to the microbiology laboratory for mycobacteriologic tests from the Kocaeli University hospital inpatients and outpatients clinics were retrospectively analyzed in this study. Smear, culture, and polymerase chain reaction (PCR) results were examined and differences in these results considered as discordant. Patients with discordant results were clinically evaluated retrospectively by a chest physician through investigation of patient's records and if necessary through telephone interview. The patients were asked whether they were on treatment and whether they had other tests (eg, computed tomography, blood tests, etc.).
A total of 2569 clinical specimens obtained from 1511 patients were tested for the presence of M. tuberculosis. Two or 3 samples were obtained from 1 patient. A total of 529 (35%) patients were women, and 982 (65%) were men. The mean age was 51 (range, . Clinical specimens were stained with auramine O fluorochrome and examined by standard procedures. Fluorochrome stain positive or suspected smears were confirmed by examination with Ziehl-Neelsen stain method. A Mycobacterium tuberculosis culture growth technique (Löwen-stein-Jensen and/or BACTEC 960) and PCR were also performed. If both clinical diagnosis and culture results were positive, the results were considered true positive.
Processing of Specimens
All specimens derived from nonsterile sites were decontaminated and digested by the addition of an equal volume of NaOH-citrate-N-acetyl-L-cysteine at room temperature for 15 minutes. Phosphate buffer (pH 6.8) was added to the 50-mL mark, and the contents of the tube were mixed and centrifuged for 15 minutes at 3500g. The supernatant was then discarded, and the sediment was resuspended in phosphate buffer up to a total volume of 5 mL and vigorously mixed. This suspension was used for culture and smear. Direct smears were prepared for screening by fluorochrome staining (auramine O) and confirmation by Ziehl-Neelsen staining. Cultures for mycobacteria were performed by inoculating 0.2 mL of sediment into Löwenstein-Jensen agar slant and 0.5 mL of sediment into a mycobacteria growth indicator tube (MGIT). All MGIT tubes were supplemented with the antimicrobial solutions (PANTA: polymyxin B, azlocillin, nalidixic acid, trimethoprim, amphotericin B) provided by the manufacturer (Becton Dickinson, Sparks, MD). After inoculation, Löwenstein-Jensen agar slants were placed at 35 to 37°C for 8 weeks, and MGIT tubes were placed in to the BACTEC MGIT 960 system and were incubated at 35°C to 37°C for 6 weeks. Cultures that signaled positive in the MGIT system had a 50-L aliquot removed and inoculated onto the surface of a sheep blood agar plate to determine whether bacteria contaminated the culture. In addition, a smear was prepared and stained with Ziehl-Neelsen stain and observed for presence of mycobacteria.
Differentiation of mycobacterial isolates as M. tuberculosis or Mycobacterium spp. other than tuberculosis was based on the BACTEC p-nitro-␣-acetylamino-␤-hydroxy-propiophenone (NAP) test according to the manufacturer's recommendations. The NAP tubes whose growth units Յ10 were defined as M. tuberculosis.
Before DNA isolation, sputa were mechanically homogenized and liquified with 1 volume with N-acetyl-L-cysteine (NALC)-NaOH. The liquified material was sedimented in refrigerated centrifuge at 4500g for 10 minutes. After neutralization, the pellet was resuspended in 1 mL of distilled water. Urine and other liquid samples were centrifuged at 4500g for 10 minutes, and resulting pellets were treated as described above. Cerebrospinal fluid was concentrated only by centrifugation; there was no further treatment. Biopsy samples were mechanically homogenized, and homogenate was resuspended in phosphate-buffered saline and adding 20 L Proteinase K per 200 L for incubation (56°C, 1 hour) to homogenate complete lysis.
PCR
The real-time PCR was performed as follows: a standard protocol for magnetic particle extraction (NucliSENSeasyMAG; bioMérieux, Boxtel, Holland) and amplification (The iCycler iQ, v3.0a; Bio Rad Laboratories, Hercules, CA) of M. tuberculosis DNA was performed. HotStarTaq DNA polymerase (QIAGEN GmbH, Hilden, Germany) was used on the amplification step of M. tuberculosis DNA. The primer set used to amplify the 105-bp IS6110 gene fragment consisted of forward 5Ј-GGCTGTGGGTAGCAGACC-3Ј and reverse 5Ј-CGGGTCCAGATGGCTTGC-3Ј primers that are specific for the M. tuberculosis bacterium. The internal oligonucleotide probe was labeled with fluorescent dyes 5-carboxyfluoroscein (FAM) on the 5Ј end and N, N, NЈ, NЈ-tetramethyl-6-carboxyrhodamine (TAMRA) on the 3Ј end. The internal probe hybridizes within the 163-bp region amplified by the PCR primers and has the sequence 5Ј-(FAM)-TGTCGACCT-GGGCAGGGTTCG-(TAMRA)-3Ј. 10 
Statistical Analysis
The sensitivity, specificity, positive and negative predictive values (PPV and NPV, respectively), and accuracy of the assay were calculated using the culture results or both clinical diagnosis and culture results as reference standard.
RESULTS
In a 1-year period, 2569 clinical specimens obtained from 1511 patients and referred to the laboratory for mycobacteriologic tests were included in the study. In total, 233 patients were tested only with smear and 6 (2.5%) of them were AFB positive (Table 1) . However, 2 of these 6 patients were already under anti-TB therapy. Specimens from these patients were collected for monitoring the treatment efficacy. Therefore, only 4 positive results were obtained from the other 231 patients (1.7%).
In total, 1815 samples collected from 1159 patients were cultured with Löwenstein-Jensen and/or BACTEC MGIT 960. Eighty-three of 1159 patients were culture positive (7.2%), and 120 of 1815 samples were culture positive (6.6%; Table 1 ). Sixty-three of 120 samples (53%) were both smear and culture positive. Three of 1695 culture negative samples were smear positive (Table 2 ). These three patients were clinically accepted to have TB, and they received anti-TB therapy. On the basis of culture results as a gold standard, sensitivity, specificity, PPV, AFB, acid-fast bacillus; PCR, polymerase chain reaction. AFB, acid-fast bacillus; PCR, polymerase chain reaction; PPV, positive predictive value; NPV, negative predictive value.
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and NPV of AFB smear was 52.5%, 99.8%, 95.4%, and 96.7%, respectively ( Table 2 ).
In total, 317 patients were tested by PCR method. M. tuberculosis DNA was detected in 31 (9.8%) of them. Sixty-six of these 317 patients (21%) were not tested for AFB and culture. Three of these 66 patients' samples were PCR positive (4.5%; Table 1 ). These 3 patients were accepted clinically to have TB, and anti-TB therapy was initiated. Of the 317 patients' samples that were tested with PCR, 53 were tested with AFB only. Three of these 53 patients' samples were positive (5.6%) with PCR, 2 of these 3 were also AFB positive, but 1 of them was AFB negative (Table 1) . These three patients were accepted clinically to have TB, and anti-TB therapy was initiated. Of the 317 patients' samples that were tested with PCR, 198 (62.4%) were tested with both AFB and culture. Twentyfive (12.6%) of these 198 patients' samples were positive with PCR (Table 1) . Among these 198 patients' samples, 36 were respiratory, 64 were from sterile body fluids, 10 were abscess, and 49 were urine, whereas 39 originated from other body sites (Table 3) .
Of 25 PCR-positive samples, 6 (24%) were culture positive, and 19 (76%) were culture negative ( Table 2 ). These 19 patients were likely to represent false-positive results because 10 of them were accepted clinically as having TB by clinicians and were given anti-TB therapy. The other 9 did not receive anti-TB therapy. On the other hand, 13 of these 198 patients were culture positive (6.5%), 7 of these culture-positive patients were PCR negative and were accepted as falsenegative (sensitivity of PCR 46%; Tables 2 and 4). Only 1 specimen was evaluated from 5 of these 7 false-negative patients, and 2 specimens were examined from the remaining 2 patients. Two of these 7 false-negative patients' specimens were pulmonary, 1 was peritoneal fluid, and 4 were from other body sites (Table 3) .
Performance of PCR according to the nature of clinical samples compared with culture as a gold standard was shown in Table 3 . Sensitivity and PPV were lowest in the other body sites. As shown in Table 4 , 5 of 6 culture-positive and PCRpositive (true-positive) patients were AFB smear positive, and 1 of them was AFB smear negative. On the other hand, 5 of 7 culture-positive and PCR-negative (false-negative) patients were AFB smear positive, and 2 of them were AFB smear negative. On the basis of culture results as a gold standard, sensitivity, specificity, PPV, and NPV of PCR were 46%, 89.7%, 24%, and 95.9%, respectively (Tables 2-4).
DISCUSSION
The findings presented in this study provide information on routine using pattern and the performance characteristics of laboratory tests in the diagnosis of different forms of TB by examining respiratory and nonrespiratory specimens in a university hospital, which is situated in a geographic region with middle prevalence for TB (27-44 new cases annually/100,000 population). 11, 12 We documented routine using outcomes associated with daily use of TB diagnostic tests.
In 1 year, 233 (15.4%) of 1511 patients were tested only with smear, and 2.5% of them were AFB positive, which reflects that clinicians prefer only AFB smear as a screening test when there is a low clinical suspicion for TB. On the other hand, 961 (63.6%) of the 1511 patients were tested with AFB and culture, and 7.2% of them were culture positive, reflecting an unnecessarily low threshold among clinicians in suspecting TB (Table 1) . Clinicians use culture as a screening tool for passive surveillance of TB. In countries with middle prevalence of TB, nearly 30% of the clinically suspected patients would be expected to have culture positivity. 5, 13 Sensitivity of the AFB smear (52%) is an expected result. 14 Three AFB-positive, culturenegative patients were accepted to have TB because they had high clinical suspicion for TB, and their anti-TB therapy was initiated. Supervision and reexamination of these positive smears point out -50  ---AFB negative  188  1  2  19  166  33  89, 7  5  98, 8  Total  198  6  7  19  166  46  89  23  93, 4 AFB, acid-fast bacillus; PCR, polymerase chain reaction; PPV, positive predictive value; NPV, negative predictive value.
Dundar et al that there may be a possible technical error during homogenization-decontamination step of the culture. Three hundred seventeen (21%) of the 1511 patients were tested with PCR, but 66 (21%) of these 317 patients were tested with neither AFB nor culture. Three (4.5%) of these 66 patients were positive with PCR, which means selected patients for PCR alone had low clinical suspicion. Nearly, all experienced authors point that PCR has shown a poor reproducibility and false-positivity in clinical specimens. Significant variability in the sensitivity and specificity of PCR has been observed in different studies. 2, 15 Centers for Disease Control and Prevention does not recommend the use of PCR for regular workup of TB suspects. 16 It is recommended that PCR should always be performed in conjunction with microscopy and culture and that the results should be interpreted alongside the patient's clinical data. 8, 9 PCR cannot replace the smear, which determines infectiousness, or culture, which is essential in species identification and susceptibility testing. 4 Of the 317 patients' samples that were tested with PCR, 53 (17%) were tested with AFB but not with culture. Three of these 53 patients' samples were positive (5.6%), 2 of these were AFB positive, and 1 was AFB negative. These 3 patients were clinically accepted as having TB, and their therapy began. A positive PCR for a smear-positive specimen would be indicative of real TB. However, a positive PCR for a smear-negative specimen would provide less clinical certainty for the diagnosis of TB, and the results should be interpreted with caution and always in parallel with clinical information. 2 In smear-negative patients, the PCR may also be of value, although it should be used with more caution. PCR should not be used in smearnegative specimens as a screen to rule out the disease. [17] [18] [19] Of the 317 patients' samples that were tested with PCR, 198 (62.4%) were tested with AFB and culture. Twenty-five of these 198 patients were PCR positive (12.6%). On the other hand, 13 of these 198 patients were culture positive (6.5%). On the basis of culture results as a gold standard, 6 of the PCRpositive patients were true positive, 19 were false positive, and 7 of the 13 culture-positive patients were false negative (Tables  2-4) . PCR-positive, culture-negative 19 patients were likely to represent false-positive results because 10 of them were accepted clinically as having TB and were given anti-TB therapy, and the other 9 were not accepted clinically as having TB and were not given anti-TB therapy ( Table 2 ). None of these 9 patients developed TB during follow-up. In a study, it was reported that no patients with positive PCR but negative culture developed active TB during 18 months follow-up. 20 It is well known that the sensitivity of cultures for the diagnosis of TB is not ideal, particularly for paucibacillary forms of the disease, and several cases may have been missed by cultures alone. On the other hand, some may be misclassified when the diagnosis was based on clinical criteria, resulting in overestimation or underestimation of the performance of TB PCR tests. Therefore, in the absence of a gold standard reference method, it is not possible to evaluate accurately the performance of a new test for the diagnosis of TB. 2 PCR is warranted on smear-positive sputum samples and potentially on smear-negative samples if the clinical presentation is highly suggestive of TB. 21 In smear-negative patients, PCR may also be of value, although it should be used with more caution. Most positive PCR results will be indicative of a real TB infection. If clinical suspicion is high, treatment could be begun, but in the face of uncertainty, waiting until the culture results become available before beginning the treatment is perhaps the best choice. Because the patient is smear negative, there is presumably less risk of infecting others than in the smear-positive situation. 18 On the basis of culture results as a gold standard, sensitivity, specificity, PPV, and NPV of PCR were 46%, 89.7%, 24%, and 95.9%, respectively (Table 2 ). ***Laraque et al reported that sensitivity, specificity, PPV, and NPV of PCR were 79.3%, 80.3%, 83.1%, and 76.0%, respectively, in AFBnegative patients, whereas 97.5%, 93.6%, 95.1%, and 96.8%, respectively, in AFB-positive patients. 22 PPV is mainly affected by the prevalence of TB in the studied population and the proportion of smear-positive specimens. 2 Laraque et al reported that of the 16,511 patients being evaluated for pulmonary TB, 4642 (28.1%) had specimens that tested positive for AFB on smear. 22 In our study, 66 of 1815 patients (3.6%) were AFB positive ( Table 2) . Selection of appropriate patients for further testing and exclusion of low-risk patients from microbiological testing by experienced clinicians may help to optimize the PPV of these new and relatively expensive tests. 5 It is also known that cost analyses are critical for TB control and TB policies. 23 Further analyses related with cost-effectiveness should also be performed.
Because of the retrospective nature of this study, we provided the patients data especially from chart records. Therefore, specimen collection and diagnostic and therapeutic criteria could not be standardized. But still, it was established that some diagnostic tests were not use clinically in appropriate indication. Health institutions should systematically observe the new developed techniques and their routine using patterns.
PCR should always be performed in conjunction with microscopy and culture, and the results should be interpreted alongside clinical data. 9, 24 On the basis of our findings and clinical considerations, we do not recommend that PCR replace culture nor that it be used routinely for the diagnosis of smear-negative TB.
